Objective To assess the impact of cyclophosphamide (CYC) on the health‐related quality of
life (HRQOL) of patients with scleroderma after 12 months of treatment. Methods One …

Objective. To study the causes of hospitalizations and predictors of subsequent adverse
outcomes for contemporary cohorts of patients with systemic sclerosis (SSc) in the USA …

Elevated pulmonary levels of CCL18 have been associated with influx of T lymphocytes,
collagen accumulation, and a decline in lung function in pulmonary fibrosis patients. We …

Autologous hematopoietic stem cell transplantation (HSCT) utilizing a myeloablative
regimen containing total body irradiation has been performed in patients with systemic …

Objective Gastrointestinal tract (GIT) involvement occurs in∼ 90% of patients with systemic
sclerosis (SSc) and has a major impact on health‐related quality of life (HRQOL). We …

Objective This pilot study was aimed at evaluating the efficacy and safety of a protocol-
based treatment strategy combining mycophenolate mofetil (MMF), intravenous (IV) …

Substantial progress has been made in the past 10 years in the development and validation
of outcome measures and refinement of trial methodology for systemic sclerosis …

Despite the intense interest in biological agents, traditional immunosuppressive drugs
remain the mainstays of treatment for systemic rheumatic diseases that involve the lung …

The interpretation of pulmonary function tests (PFTs) in patients with connective tissue
disease poses considerable difficulties in clinical practice. In established lung disease …

Pulmonary disease is the most common cause of death in patients with systemic sclerosis.
This article discusses the variety of ways the lung is affected in systemic sclerosis. These …